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Breast cancer (BC) is a widespread, heterogenous and complex neoplastic disease that affects nearly one 
of eight women during their lifetime. It is characterized by an abnormal cell proliferation within the 
mammary glands, changes in cell genetic material and a polarization of cellular behaviour towards a 
malignant stage. In advanced stages, cells can disseminate from the primary focus and invade different 
tissues via bloodstream or lymphatic system, starting a process known as metastasis (American Cancer 
Society, 2021; Akram et al., 2017; Martínez-Campa et al., 2017).  
Metastatic processes start when a primary solid tumour invades the adjacent tissue and spreads to the 
neighbouring, reaching distant organs. Early stages of metastasis strongly rely on epithelial to 
mesenchymal transition (EMT), following extravasation, colonization and differentiation. Therefore, 
epithelial cells are the major cellular type involved in tumorigenic processes, generating carcinomas. In 
spite of this, muscle cells and myoepithelial cells can generate tumours, sarcomas and myoepithelial 
carcinomas respectively, although this happens with a lesser frequency (American Cancer Society, 2021; 
Nurzadeh et al., 2021; Akram et al., 2017). 
Attending to its histological and molecular characteristics, breast cancer can be divided into different 
groups (Akram et al., 2017). Commonly, breast cancer is categorized considering distinctive molecular 
and phenotypical features: 
- Breast cancer expressing hormonal receptors: estrogen receptor (ER+) and progesterone receptor 
(PR+). 
- Breast cancer expressing human epidermal growth receptor 2 (HER2+). 
- Triple negative breast cancer (TNBC): tumours which do not express any receptor. 
1. Epidemiology 
 
Breast cancer is the most common cancer in women and consequently, the primary cause of mortality 
due to cancer in female, with 1.2 million of new cases being diagnosed and 500000 associated deaths per 
year. In Spain, 5-year survival expectancy is close to 85%, calculating 25000 annual new cases, an 
incidence that is showing a progressive growth in the last decades. Most cases are diagnosed in patients 
between 35 and 80 years old (Martín et al., 2015).  
Breast cancer incidence is tightly related to socioeconomic situation. As a result, higher breast cancer 
rates are associated to western countries in USA and Europe. Accordingly, Asia and Africa registered 
lower incidence rates, especially in underdeveloped countries, as shown in Figure 1 (Martín et al., 2015). 
In spite of this, general advances in diagnosis and treatment of this pathology, combined with promising 
new approaches based on personalized medicine, can serve as the foundation to reduce breast cancer 
incidence.  






The precise mechanisms that trigger breast cancer onset are still unknown. However, there is a vast list 
of clinical and genetic factors associated to this pathology that can impact directly or indirectly into the 
development of the disease. These factors can be classified into modifiable (endogenous estrogens levels, 
obesity, hormone therapy, alcohol consumption, etc.) and non-modifiable (gene mutations, family and 
reproductive history, age, etc.). However, there are some controversial opinions regarding whether some 
factors are modifiable or not (Barzaman et al., 2020; Martín et al., 2015; Samavat & Kurzer, 2015). Hiatt 
et al. (2020) proposed a conceptual model of breast cancer etiology, illustrated in Figure 2.  
One important factor is age, which can be in turn related to other factors. Age increases breast cancer 
incidence progressively, until the range of 40-50 years, with a following stabilization. Survival rate also 
decreases to the growing age. Socioeconomic level has also an important impact, as stated before, 
affecting women with a higher educational, economical and occupational level, especially the ones 
residing in urban areas. Nevertheless, this is a challenging factor to measure. Lifestyle is another factor 
to take into consideration, being primarily important the association of breast cancer with sedentarism 
and overweight, highly related with diet. At the same time, alcohol intake can raise the level of estrogen 
related hormones by stimulating estrogen receptor pathways and have a negative impact in breast cancer 
pathology (Hiatt et al., 2020; Naeem et al., 2019; Martín et al., 2015).   
Breast cancer progression can be favoured by hereditary factors as the presence of family members with 
breast or ovary cancer. In this way, the closer the kinship or the earlier the first case, the greater probability 
of developing breast cancer. One third of patients reporting a family case of breast cancer are carriers of 
an inheritable mutation in BRCA1 or BRCA2, HER2, PIKC3A genes. These are important genes because 
they play a functional role in homologous recombination and DNA damage. Healthy women carrying a 
Figure 1. Breast cancer worldwide incidence. Estimated age-standardized incidence rates in 2020. Source: GLOBOCAN (2021, 
online).  
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mutation in BRCA1 and BRCA2 genes increase up to a 60% the probability of developing breast cancer 
in the long term (Naeem et al., 2019; Martín et al., 2015).    
Mammary lesions as sclerosing adenosis, intraductal papilloma, ductal atypical hyperplasia, etc.  strongly 
increment the risk of developing breast cancer. Regarding this, hormonal treatment can also result in this 
pathology. For example, prolonged exposure to high estrogen levels, both endogenous or exogenous, can 
influence breast cancer development, that may be the case of late menopause, premature menarche or 
women that have not given birth (Naeem et al., 2019; Martín et al., 2015).   
These biological, behavioural, social and physical relationships, demonstrate the complexity of breast 
cancer etiology. The study of these causative factors and interconnections between them, can help to 
stratify patients with higher predisposition to develop the disease and be further supervised by specialists, 
substantially increasing life expectancy. 
3. Estrogen role in breast cancer 
Estrogen implication in breast cancer development was hypothesized when bilateral oophorectomy was 
associated to a significantly reduced breast cancer risk. This reduction was even greater when ovaries 
were removed at an early age. This added to the fact that 2/3 of breast cancer tumours are ER+ and 
respond to circulating estrogen levels, sheds a light into the importance of deciphering the estrogen-
dependent mechanisms involved in breast cancer progression (Samavat & Kurzer, 2015).  
Figure 2. Conceptual model of breast cancer etiology. Causative factors are displayed in four domains: social (orange), 
physical (blue), biological (yellow) and behavioral (green). The thickness of arrows indicates strength of the association, as well 
as quality of data indicated as solid, broken or dotted arrows. The greater strength and quality of data is pictured as a thick 
solid arrow. Source: Hiatt et al. (2020).  
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As stated before, estrogen levels can influence breast cancer onset and associated risk. Epidemiological 
studies have consistently shown a 2–3-fold increase in breast cancer risk in women with elevated blood 
estrogen levels. The most common circulating estrogens are estradiol, estrone and estriol. Estradiol is 
secreted by ovarian granulosa cells and is the most biologically active estrogen form. Estradiol can also 
be formed by estrone conversion through 17β-hydroxysteroid dehydrogenase enzyme. Ovarian theca cells 
can secret androstenedione during the menstrual cycle, which acts as a precursor of estrone and 
testosterone. This last hormone can also be converted into estradiol by aromatase enzyme in peripheral 
tissues, highly important in post-menopausal woman due to cessation of follicular function (Samavat & 
Kurzer, 2015). 
Estrogens play a major role in promoting breast epithelium proliferation in both normal and neoplastic 
tissues. Thus, they have been considered as breast carcinogens due to their participation in three principal 
processes: hormonal activity-mediated cell proliferation (1), genotoxic effects by the increase of mutation 
rates derived from cytochrome P450 metabolic activity (2) and aneuploidy induction (3) (Russo & Russo, 
2006).  
In mouse models, tumorigenic effects of estrogens are associated with hyperprolactinemia and pituitary 
hyperplasia increasing the number of hyperplastic prolactin-secreting cells. Estrogen binding to nuclear 
receptor alpha (ER-α) is the main mechanism involved in carcinogenicity, entailing a potent stimulus on 
breast cancer cell proliferation through growth factor production. Moreover, several studies have claimed 
that specific estrogen metabolites might generate several DNA mutations that may trigger breast cancer 
onset (Russo & Russo, 2006). 
4. Breast cancer treatment   
4.1. Anti-estrogenic therapy (hormonotherapy) 
One of the main goals in the treatment of breast cancer is to neutralize the effects of estrogens on the 
breast, due to their involvement in breast cancer progression, especially in breast cancer expressing 
hormone receptors (Barzaman et al., 2020; Russo & Russo, 2006). The pharmacological strategies 
employed to selectively neutralize the effects of estrogens on the breast are: 
 The use of Selective Estrogen Receptor Modulators (SERMs). These are molecules that bind and 
block the estrogen receptor (ER), thus preventing estrogen binding. The most common are 
tamoxifen, fulvestrant and raloxifene. Nevertheless, they can exert their anti-neoplastic function 
non-specifically in other tissues. For example, tamoxifen can target estrogen in the uterus, liver 
or bone, leading to osteoporosis, among other malignancies (Barzaman et al., 2020; Akram et 
al., 2017). 
 The use of Selective Estrogen Enzyme Modulators (SEEMs). These molecules inhibit enzymes 
involved in the synthesis of steroid hormones (therefore preventing estrogen synthesis) or 
activate of enzymes related with estrogen inhibition. Aromatase inhibitors are an important 
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example of this molecules, preventing ovary hormone production. This is the case of letrozole, 
anastrozole and exemestane (Barzaman et al., 2020).  
Toxic effects of anti-estrogenic therapy are not as significant as those linked to other cytotoxic drugs, 
although there are some side effects associated to this treatment. Even though, medical indications for 
discontinuing the use of this treatment include more severe affections (Akram et al., 2017). 
4.2. Chemotherapy 
Chemotherapy is traditionally one of the most common breast cancer treatments, especially in aggressive 
subtypes. Chemotherapeutic agents include: anthracyclines (epirubicin, doxorubicin), taxanes (paclitaxel, 
docetaxel), capecitabine, vinorelbine, platinum drugs (cisplatin, carboplatin), gemcitabine, trastuzumab 
and angiogenesis inhibitors. However, chemotherapy has devastating side effects, mainly caused by the 
unspecific targeting, that may attack all growing cells including immune cells, therefore decreasing 
immunological responses. At the tumour microenvironment level, chemotherapeutic agents have positive 
effects, helping immune cells to eradicate or supress tumour growth by selectively polarizing immune 
cell population (Barzaman et al., 2020).  
In this work, we will test two common chemotherapeutic drugs: docetaxel and doxorubicin. The first one 
is a taxane that acts stabilizing microtubules through tubulin binding, consequently preventing cell 
division. The second one is an anthracycline that works by intercalation between double DNA helix, 
inhibiting DNA dependent DNase and RNA polymerases. This consequently interrupts DNA replication, 
therefore doxorubicin has a stronger effect on the S phase of cell cycle. Rupture of DNA strands is 
associated with formation of free radicals, responsible for the inhibition of respiratory chain enzymes in 
mitochondria and membrane lipid oxidation (Saloustros et al., 2008; Czeczuga-Semeniuk et al., 2004). 
A correct chemotherapeutic dosage is needed for effective treatment, as high doses could completely 
supress immune responses. The search of an adequate chemotherapeutic dose with minimal side effects 
led to metronomic chemotherapy (MTC). This treatment is based on regular and low dosage 
administration of chemotherapeutic agents, being specifically important in treating angiogenesis and 
vasculogenesis. It can also restore anti-tumoral responses within the tumour microenvironment, 
specifically targeting Treg cells (Barzaman et al., 2020). 
Chemotherapeutic agents can also promote immune cell death (ICD), mainly mediated by calreticulin. 
This is why the synergistic effect of chemotherapeutic and immunotherapy can enhance treatment 
effectiveness. As an example, according to Barzaman et al. (2020), it was observed that chemotherapy in 
combination with trastuzumab could increase breast cancer patients survival in a 35%.  What is more, 
antigens released during chemotherapy within the tumour microenvironment, could be helpful in 
immunotherapeutic strategies. Chemotherapeutic drugs used in this project (docetaxel and doxorubicin), 
can both increase the number of T and NK cells and reduce B cells or activate NK cells in the case of 
docetaxel (Barzaman et al., 2020).  




Radiation therapy (RT) is reported to be effective especially in early stages of breast cancer and is 
commonly used in combination with breast conserving surgery. As radiation kills malignant cancer cells, 
radiation is used to eliminate reminiscent cells in the tumoral area (Akram et al., 2017). According to 
Piroth et al. (2019), whole-breast irradiation with a total dose of 50 Gy can reduce local recurrence rate 
by 70-88%. However, these techniques can increase cardiac toxicity, especially in left-sided breast cancer 
patients, leading to radiation-induced heart disease (RIHD) (Piroth et al., 2019). 
Nevertheless, total dosage was significantly reduced over the past few years thanks to the application of 
new techniques as three-dimensional treatment planning, optimizing the treatment according to patient’s 
anatomy. For example, average dose in 1970s was 13.3 Gy, however, in 2007 main dosage was reduced 
to 2.3 Gy. These significantly diminished therapy complications as skin desquamation, edema, late 
fibrosis, etc. (Piroth et al., 2019; Mcdonald et al., 2016).  
Role of microRNAs in breast cancer 
MicroRNAs, commonly known as miRNAs, are post-transcriptional gene regulators that participate in 
normal and disease-associated cellular processes. Therefore, these non-coding RNA molecules are a 
fundamental basis to study the etiopathogenesis of several human diseases, being cancer one of them 
(Singh & Mo, 2013).  
miRNAs are single-stranded, non-protein coding, conserved, endogenous molecules, ranging from 19 to 
25 nucleotides in length. It is thought that the human genome contains 2654 mature miRNAs, constituting 
1-2% of eukaryotic genome. These molecules coordinate multiple pathways involving gene activation or 
more frequently, gene repression. According to Loh et al. (2019) it is believed that they could regulate 
one-third of protein coding genes. They exert their function by degradation (if there is perfect 
complementarity between miRNA and mRNA sequences) and translational repression (if there is partial 
complementarity), binding to the target mRNAs (messenger RNA). What is more, one single mRNA can 
be cooperatively regulated and targeted by multiple miRNAs, amplifying their impact (Loh et al., 2019; 
Singh & Mo, 2013).  
The biogenesis of mature miRNA involves a series of biological processes gathered in Figure 3A. The 
process starts by a primary miRNA transcript (pri-miRNA), that is transcribed in the nucleus by RNA 
polymerase II/III. The resulting molecules are nucleotide-based structures with local stem loops, a 5’ cap 
and a poly-A tail. Pri-miRNA is processed by Drosha (RNAse III-type endonuclease) into a 70-nt hairpin 
structure known as precursor miRNA (pre-miRNA). This pre-miRNA is exported from the nucleus to the 
cytoplasm by exportin 5 RanGTP-dependent nuclear transport and loaded onto Dicer. This RNAse III 
enzyme, thanks to the aid of transactivation response RNA binding protein (TRBP), generates a double-
stranded structure formed by mature miRNA/antisense miRNA duplex. The latter is usually degraded, 
whereas the long mature miRNA strand is incorporated into the miRNA-induced silencing complex 
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(RISC) leading to gene silencing. Gene silencing mechanism of action depends on mature miRNA 
binding to its seed sequence (2-8 nucleotides from the 5’- end) to the 3’-UTR (or 5’-UTR and open 
reading frame (ORF)) region of the target mRNA (Loh et al., 2019; Hamam et al., 2017). 
miRNAs participate in different breast cancer cellular pathways (proliferation, apoptosis, metastasis, 
cancer recurrence and chemoresistance, among others), considered the hallmarks of cancer disease. 
Depending on their overall action, they can be classified into oncogenic (oncomiR) or tumour suppressor 
(tsmiR), targeting tumour suppressor genes or oncogenes, respectively (Nurzadeh et al., 2021; Loh et al., 
2019) (Figure 3B). 
 
1. Regulatory role of miRNAs involved in breast cancer  
Few studies have evaluated different patterns of miRNA expression in breast cancer patients. Establishing 
the main pathways related to these changes in expression and how to regulate them, has become the main 
focus on novel breast cancer miRNA-therapy. As a general overview, there are some miRNAs that are 
significantly dysregulated in breast cancer (miR-125b, miR-145, miR-21 and miR-155) (Singh et al., 
2013). In this work, we are going to cite the most important miRNAs involved in breast cancer pathology 
and relate them to the hallmarks of the disease.  
Figure 3. (A) MicroRNA biogenesis and modulation of miRNA activity. miRNA genes are transcribed to produce primary miRNA 
transcripts. Subsequently, Drosha cleaves the pri-miRNA into a precursor miRNA transcript (pre-miRNA) then transported into the 
cytoplasm via nuclear pore by exportin 5. In the cytoplasm,  pre-miRNA is modified by the Dicer and TRBP complex to form a mature 
miRNA duplex. The miRNA duplex is unwound by helicase into two single-stranded miRNAs and incorporated into RISC complex. 
This complex can then bind to target mRNA and exert its inhibitory function through translational block or miRNA degradation. (B) 
Regulatory mechanisms of miRNAs in tumorigenesis. Within the tumoral microenvironment, cancer cells undergo high expression 
of oncomiRs and low expression of tsmiRs. This leads to inhibition of tumour suppressor genes and enhancement of oncogene 
expression, respectively, which favors tumoral processes. Source: Loh et al. (2019).  
A B 
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1.1. Cell proliferation and cell cycle regulation  
Cell proliferation is the principal process involved in breast cancer development and is tightly regulated 
by cell cycle progression. Cyclin E1 is an important regulator of G1-S cell cycle transition and is the target 
of tsmiRs miR-497, miR-483 and miR-16. Overexpression of this miRNAs inhibited cell proliferation 
and cell cycle progression, preventing DNA synthesis during S-phase (Loh et al., 2019). 
miR-221/222 cluster overexpression was demonstrated to be involved in S phase initiation and induction 
of cell proliferation. Its principal targets are cell cycle inhibitors like p27 and p57, resulting in Wnt, Notch 
and MAPK signalling pathways promotion (Nurzadeh et al., 2021).  
miR-106A/363 cluster is a paralogue of miR-17/92 and encodes for miR‑106a, miR‑18b, miR‑20b, 
miR‑19b, miR-92a and miR‑363. The cluster was related with PI3K/AKT pathway and associated to 
tumour size and lymph node metastasis. Specifically, this miRNA cluster regulates PTEN, inhibiting its 
expression, consequently increasing cell growth, proliferation and metastasis through DNA synthesis 
(Nurzadeh et al., 2020; Fang et al., 2017).  
Breast cancer cell viability can also be increased by upregulation of some protein kinases and 
downregulation of its inhibitors. miR-143 and miR-455 expression counteracts the proliferative effects 
of cyclin D1, MAP3K7 (mitogen-activated protein kinase) and CDK14 (Cdc2-related protein kinase). 
miR-424 overexpression allows the inhibition of cellular proliferation by arresting cells in the G2-M 
phase. This anti-oncogenic function of miR-424 is dependent on its binding to CDK1 (Loh et al., 2019). 
1.2. Invasion and metastasis 
Invasiveness and metastatic potential of cancerous cells lies on their poor adhesion to extracellular matrix 
and consequent loss of cell-matrix interactions. This is happens because of EMT process, characterized 
by the loss of E-cadherin and switch to N-cadherin, reducing cell localization and interactions, allowing 
them to invade and metastasize distant organs via blood or lymphatic systems (Loh et al., 2019). There 
are many miRs related to these processes. Thus, overexpression of miR-200c/141 cluster in breast cancer 
cells is related to increased C-JUN, C-FOS and FOSB mRNAs, upregulating the expression of Serpine 
B2, a mediator of cell metastasis in the lungs and lymph nodes (Nurzadeh et al., 2021; Loh et al., 2019). 
miR-10b and miR-221/222 cluster are also responsible for inducing EMT by targeting TWIST-1 gene 
(miR-10b) or suppressing Notch3 (Nurzadeh et al., 2021; Loh et al., 2019). 
Wnt/β-catenin signalling pathway was shown to be related to metastatic processes in breast cancer, 
regulating EMT. miR-148a, a target for WNT-1 (a negative regulator of Wnt/β-catenin pathway) is 
downregulated in cancerous processes and related to an increase in migration and invasion capacity. 
Additionally, miR-340 is thought to inhibit migration, invasion and metastasis by also targeting this 
particular pathway. Moreover, miR-29a is also related to EMT and metastasis, specifically promoting 
these features through tristetraprolin targeting (Singh & Mo, 2013).  
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On the other hand, miR-497 and miR-204 had a suppressive role on cell proliferation and migration, 
specifically supressing SMAD7 gene expression in the case of miR-497. As a consequence, immune 
response and tumour immune escape are inhibited (Loh et al., 2019). 
Finally, miR-17/92 cluster is also involved in invasion and metastasis, however it was reported that miR-
17 could affect differentially depending on the breast cancer subtype implicated. In some cases, it can 
supress c-Myc through ROCK signalling pathway and PTEN suppression, leading to the activation of 
Wnt/β-catenin pathway. However, in other cases it can inhibit cell proliferation through ETV1 
suppression, acting as a tumour suppressor  (Nurzadeh et al., 2021).  
1.3. Apoptotic response and cell death 
Apoptosis is a defence mechanism induced by alterations in chromosomal or genetic content of normal 
cells. This means cell viability can be increased if some point of the apoptotic process is disrupted. Cancer 
cells evade apoptotic response through multiple mechanisms: loss of tumour suppressor proteins, 
dysregulation of caspase activity, upregulation of pro-survival regulators, downregulation of pro-
apoptotic factors and deactivation of death ligands (Loh et al., 2019). 
For instance, miR-204 overexpression promotes apoptosis by targeting JAK2 and decreasing anti-
apoptotic proteins like Bcl-2 and survivin. miR-148a overexpression also reduces cell viability and 
chemoresistance by supressing BCL-2, its main target (Loh et al., 2019). 
miR-21 and miR-203 are oncogenic miRNAs targeted by an endogenous protein known as kallistatin. 
This protein induces cell death by activating caspase-3 in breast cancer cells. Kallistatin inhibited miR-
21 function via AKT pathway, reducing the expression of BCL-2. This protein also inhibited miR-203 
expression levels via PKC-ERK activation increasing tumour suppressor SOCS3 (Nurzadeh et al., 2021; 
Loh et al., 2019). 
Another aspect to take into consideration is cell immortality due to telomerase activity. miR-155 is related 
to telomere protection by negatively targeting TRF1, resulting in genomic instability. As a result, miR-
155 is associated with poor clinical outcomes in some types of breast cancer. However, in other studies, 
miR-155 is associated with suppression of apoptotic processes by inducing cell cycle arrest and p53-
mediated apoptosis (Nurzadeh et al., 2021; Loh et al., 2019). 
1.4. Hypoxia and angiogenesis 
Cellular growth and invasion entail an increase in cellular metabolic activity. As cellular density rises, 
oxygen concentration decreases significantly in comparison to healthy tissues. This tumour 
microenvironmental condition, known as hypoxia, is a key regulator of angiogenic processes in breast 
cancer (Loh et al., 2019). HIF (Hypoxia-induced Factor) and VEGF (Vascular Endothelial Growth 
Factor) are two major factors that regulate critical processes including cell homeostasis and proliferation, 
metastasis and angiogenesis (Loh et al., 2019). 
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miR-210 is one of the most induced miRNAs during hypoxia, associated with HIF expression and 
angiogenesis. Another miRNA related to this process is miR-20a, a member of the miR-17/92 cluster 
capable of inducing an angiogenic pattern by overexpression of VEGFA, linking the cluster to an increase 
of VEGF levels. Finally, miR-93 overexpression can increase blood vessel formation by targeting β-
integrin repression, involved in endothelial cell separation that lead to blood vessel formation (Nurzadeh 
et al., 2021). Moreover, miR-497 and miR-140 supressed angiogenesis by regulating VEGF and HIF-1α, 
disrupting the formation of capillary structures and reducing microvascular density (Loh et al., 2019). 
Finally, several studies demonstrated that mesenchymal stem cells (MSCs) can be recruited to the tumour 
microenvironment promoting tumour progression by interacting with tumour cells. MSCs can secret 
extracellular vesicles shaping the tumoral stroma by transference of their components, including 
miRNAs. For example, miR-100 is enriched in MSC-derived exosomes. This is believed to be responsible 
for reducing VEGF expression, acting as a angiogenic suppressor (Loh et al., 2019). 
1.5. Resistance to breast cancer therapy 
One of the major obstacles in breast cancer therapy is the resistance to conventional therapies, leading to 
undesirable secondary effects. The key genes involved in breast cancer drug resistance are MDR1 
(multidrug resistance 1), MRPs (multidrug resistance-associated proteins), BCRP (breast cancer 
resistance protein), GSTπ (glutathione S-transferase π) and DNA repair genes. The first three belong to 
the ATP-binding cassette (ABC)-superfamily multidrug efflux pumps, whose function is to pump toxic 
metabolites and xenobiotics out of the cell to protect homeostasis. GSTπ is a detoxification enzyme that 
mediates the efflux of chemotherapeutic drugs. These key genes can be targeted by miRNAs that 
modulate their activity. For example, miR-451 and miR-298 regulate MDR1 in doxorubicin resistance 
(Singh & Mo, 2013). 
Another common problem in hormone-dependent breast cancer treatment is resistance to tamoxifen. miR-
15a/16 cluster is related to tamoxifen, by increasing cell proliferation and cell cycle progression. This is 
related to E2F7 factor, correlated with a poor prognosis in tamoxifen-treated patients. E2F7 
overexpression induces transcription of miR-15a/16, promoting cyclin E1 and further inducing cell 
growth (Loh et al., 2019). On the contrary, this effect can be reduced by miR-206 overexpression, thus 
reducing G1-S transition by regulating cell cycle associated proteins like p21, CDK4 and cyclin D1 (Loh 
et al., 2019). 
2. MiRNAs as molecular markers for early breast cancer detection 
As stated before, miRNAs fulfil their functions through mechanisms of action which are dependent on 
cellular content, revealing tissue or cell-specific phenotypes. Therefore, miRNome profiling could be an 
interesting technique to adjust treatments according to molecular features of cancer subtypes. This is why 
miRNAs have a unique potential to be used as biomarkers for breast cancer detection, clinical outcome 
and prognosis (Asiaf et al., 2018; Singh & Mo, 2013). 
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More importantly, miRNAs can serve as markers for the distinctive features of breast cancer pathology, 
as they are related to different mechanisms and molecular characteristics. For example, miR-200c/141 
cluster could serve as a prognostic indicator, as it is highly expressed in basal-like cancers. Levels of this 
cluster in metastatic cancers were also higher compared to localized tumours, having a potential 
application as a breast tumour metastasis biomarker as well. MiR-34, miR-10b and miR-155 are also 
considered metastasis biomarkers (Loh et al., 2019; Asiaf et al., 2018).  
Several miRNAs can also be a sign of drug resistance. This is the case of miR-200a and miR-210, whose 
plasma levels are associated to breast cancer stage and chemotherapy resistance. Patients showing high 
levels of this miRNAs are prone to chemotherapy resistance and possibly are found in an advanced stage 
of breast cancer. For instance, miR-210 levels positively correlated with brain, lung and liver internal 
organ metastasis and stage IV breast cancer (Loh et al., 2019). 
In spite of their potential application, novel miRNA biomarkers should be validated through clinical and 
analytical assays, leaning towards a personalized treatment for early diagnosed patients with breast 
cancer. This needs to be done using prognostic biomarkers in combination with validated 
prognostic/predictive factors (Barzaman et al., 2020).  
3. Therapeutic potential of miRNAs in breast cancer  
 
Due to miRNAs implication in signalling pathways related to breast cancer pathological processes, 
experts have developed a growing interest into miRNA-based therapies. Targeting specific miRNAs 
could also serve as a novel strategy to overcome drug resistance and improve therapeutic outcomes, being 
used as adjuvants for anti-cancer drugs (Nurzadeh et al., 2021; Singh & Mo, 2013). 
miRNA-based therapies rely on miRNA mimics (replacement or restoration of miRNAs) or antagomiRs 
(miRNA reduction or suppression). On one hand, miRNA mimics are aimed to restore tumour suppressor 
normal miRNA levels using RNA duplexes. This can also be achieved by DNA plasmids encoding a 
concrete miRNA gene. These technologies should be applied considering that: they should enter the 
cytoplasm, tumour suppressor activities should prevail over oncogenic miRNAs and they should also 
target the same set of regulator mRNA as the original miRNAs (Nurzadeh et al., 2021; Singh & Mo, 
2013). 
On the other hand, miRNA inhibition therapy specifically targets miRNA biogenesis or blocks miRNA 
function. This has been done by cholesterol-conjugated antimiRs (AMOs or ASOs), miRNA sponges, 
artificial miRNA (amiRNA) and CRISPR/Cas9 genome editing, among other strategies. miRNA sponges 
are competitive inhibitors fitted with several binding sites to a certain miRNA or miRNA family 
(Nurzadeh et al., 2021; Asiaf et al., 2018). 
Nowadays miRNA delivery is based on nanoparticles that rely on materials like polyethylene glycol
(PEG), inorganic nanoparticles, lipid carriers, synthetic polyethyleneimine, chitosan, atelocollagen, etc. 
(Singh & Mo, 2013). Even though, according to Nurzadeh et al. (2021) and Bazarman et al. (2020), the 
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promising literature regarding miRNA-based therapy still has some unsolved challenges regarding 
miRNA delivery such as RNA instability, poor integration into the genome, innate immune response or 
low cellular uptake among others. Nevertheless, more in-depth knowledge is required to develop these 
strategies and provide a novel approach into personalized breast cancer treatment (Kaboli et al., 2015). 
Melatonin 
Melatonin is a small indolamine secreted by the pineal gland during the night-time with a broad spectrum 
of functions (Gaspar et al., 2019). It derives from serotonin and can be synthesized in other organs apart 
from the pineal gland, acting as a intracellular mediator or paracrine signal (González-González et al., 
2019). Many of its actions are mediated by G-protein coupled melatonin receptors in cellular membranes; 
other actions seem to involve orphan receptors or binding to molecules such as calmodulin. This 
reversible, calcium-dependent binding allows the pineal hormone to modulate intracellular functions, as 
preventing ERα transcription and diminishing estradiol-ER affinity (Gaspar et al., 2019; González, 2019). 
Additionally, melatonin can detoxify free radicals and related oxygen derivatives via receptor-
independent pathways (Reiter et al., 2010).   
In general terms, melatonin actions can be summarized in: circadian rhythm synchronization (1), free-
radical neutralizer, acting as an antioxidant hormone (2), immune response stimulation through cytokines 
and interleukin production in lymphocytes and monocytes (3) and anti-neoplastic function by exerting 
anti-estrogenic actions acting over hypothalamus-hypophysis-gonads axis, acting as a SERM or SEEM 
modulator (4) (Martínez-Campa et al., 2017). 
1. Mechanisms of cancer inhibition by melatonin 
Melatonin’s anti-tumoral action has been explored in both in vivo and in vitro models of carcinogenesis 
and it has been demonstrated in a wide variety of endogenous and environmentally induced cancers. As 
shown in Figure 4 several mechanisms have been described for the well-known anti-tumoral effects of 
melatonin.  
It is reported that melatonin exerts anti-proliferative actions through a G1-S transition delay, thus 
increasing the ratio of cells in G0/G1 phase with a consequent reduction of cells in S phase, reducing DNA 
synthesis and lengthening cell cycle duration. This G0/G1 arrest is explained by an upregulation of p53 
and p21 and a downregulation of cyclin D1. However, some literature reported low to none-melatonin 
effects in apoptotic processes (Alonso-González et al., 2017). 
Moreover, tumour growth is a balance between cell proliferation and cell death. Melatonin promotes 
apoptosis in different tumoral cells lines including MCF-7 cells by regulating some factors related with 
apoptosis such as p53, p21, Bax or Bcl-2. Telomerase activity, as explained before, is a key player in cell
viability during cancerous processes. Scientific evidences reported that ER+ breast tumours had impaired 
telomerase activity when melatonin was present, meaning anti-telomerase activity of melatonin is closely 
related to its anti-estrogenic activity (Alonso-González et al., 2017).  
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Angiogenesis is mainly driven by VEGF, promoting tumour expansion and growth. Melatonin can 
counteract this effect by negatively targeting VEGF, disrupting tube formation and tubular network 
assembly. This hormone can also inhibit some other factors related to tumour growth and neutralize 
reactive oxygen species, which in hypoxic situations stabilize HIF-α, both involved in neoangiogenesis 
(Alonso-González et al., 2017; Martínez-Campa et al., 2017).  
Tumour invasiveness and motility levels highly influence cell metastatic potential. Cell surface adhesion 
molecules as E-cadherin and β-integrin are regulated by melatonin, as well as metalloproteinases 2 and 
9, involved in basal membrane degradation. This modulates structural features towards a non-invasive 
phenotype. Melatonin was also related with stress fibbers and adhesion plaques formation, associated 
with cell attachment (Alonso-González et al., 2017; Martínez-Campa et al., 2017).  
As mentioned before, melatonin stimulates immune response through cytokine and interleukin production 
in lymphocytes and monocytes. Moreover, it stimulates the recruitment of natural killer cells, monocytes, 
macrophages and lymphocytes, polarizing tumoral cells towards a favourable immunological 
environment. Additionally, stimulation of IL-2 production is the selected therapy for treating cancer 
processes. The pineal hormone was proved to enhance this interleukin production by modulating IL-2 
receptor system. Thus, melatonin supplementation alone or in combination with IL-2 and in conjunction 
Figure 4. Anti-tumoral actions of melatonin in breast cancer. Melatonin secretion exerts different 
receptor dependent or independent actions, related with breast cancer inhibition. Source: Alonso-
González et al. (2020).  
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with chemotherapeutic drugs significantly improves tumour regression and patient survival (Kubatka et 
al., 2018). 
Finally, epigenetic changes are considered as an important molecular alteration involved in cancer 
growth. Melatonin can also change DNA methylation patterns to reduce tumoral growth, acting as an 
epigenetic factor regulator (Alonso-González et al., 2017). 
2. Melatonin and breast cancer: anti-estrogenic actions 
Melatonin plays an important role on hormone-dependent breast cancer inhibition due to its ability to 
interact with either estrogen synthesis (SEEM) or with the estrogen signalling pathway (SERM), 
counteracting the effects of estrogens. The mechanism involved in the antiestrogenic actions of melatonin 
includes a decrease on ERα expression and impairment of the E2-ERα transcriptional activation. This 
effect seems to be mediated by calmodulin, which binds specifically to ERα but not to ERβ, acting as a 
calmodulin antagonist. Unlike other SERMs (tamoxifen or its derivates), melatonin does not bind to the 
ER nor changes its affinity that may interfere with estrogen binding to its receptor (Alonso-González et 
al., 2017). 
Estrogens increase cAMP in human breast cancer cells. Melatonin, through its binding to MT1 membrane 
receptors, decreases cAMP, thus counteracting the estrogen-induced ERα transcriptional activity by 
interacting with the cAMP signaling cascade (Kiefer et al., 2002).  
As stated before, estrogens can be synthesized from sources different from the ovary. In post-menopausal 
women estrogens are synthesized in the mammary tissue by transformation either from androgen 
precursors or from biologically inactive estrogens. It has been widely demonstrated the ability of this 
indolamine to inhibit both the expression and activity the enzymes involved in the synthesis or 
transformation of biologically active estrogens from androgens. The anti-aromatase effects of melatonin 
depend on its binding to MT1 receptors and have been demonstrated not only in vitro but also in vivo 
(Martínez-Campa et al., 2017; Alonso-González et al., 2017). 
 
3. Melatonin as a sensitizing agent for chemotherapy 
In the last decades, the effect of melatonin as an adjuvant agent has been investigated in many types of 
tumours using in vitro and in vivo models. Circadian disruption of nocturnal melatonin production by 
exposure to light at night has been associated with resistance to breast cancer therapy, including 
chemotherapy, suggesting that melatonin inhibition could play a role on resistance induced by 
chemotherapeutic drugs (Alonso-González et al., 2017). 
The underlying molecular mechanisms triggered by melatonin to overcome resistance are not clearly 
understood. For instance, several studies in different cell tumour lines demonstrated the ability of 
melatonin to decrease the expression of proteins involved in the drugs efflux from the cells, thus 
increasing cytotoxic drug effects (Alonso-González et al., 2020).  
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Apoptosis resistance is another mechanism of resistance to chemotherapy in breast cancer cells. It has 
been postulated that melatonin, through the downregulation of COX-2 and PI3K/AKT signalling pathway 
among others, is able to potentiate apoptosis in cancer cells treated with different chemotherapeutic drugs 
(Alonso-González et al., 2017).  
In breast tumour fibroblasts, melatonin potentiates docetaxel and vinorelbine effects on differentiation 
and aromatase activity by decreasing cyclooxygenases expression, which makes it a promising adjuvant 
for chemotherapy sensibilization. Besides in vivo and in vitro experiments, several clinical trials have 
analysed the effects of melatonin as a chemotherapy adjuvant in different types of cancer including breast 
cancer, demonstrating that this indolamine protects against undesirable side effects, increases tumour 
response to treatment and also 1-year survival rate (Alonso-González et al., 2020). 
4. Melatonin as a sensitizing agent for radiotherapy 
In recent years, several studies have showed that melatonin administration combined with radiotherapy 
is able to enhance its therapeutic effects and protect normal cells against side effects of this treatment, 
acting as a radiosensitizer. These radiosensitizing effects of this indolamine has been demonstrated both 
in vivo and in vitro and include mechanisms such as DNA repair impairment in tumour cells, leading to 
apoptosis and cell death triggered by p53 upregulation; modulation of inflammatory response reducing 
ROS production and DNA damage in normal tissues. It was also seen that melatonin can increase 
oxidative stress at tumoral level and modulate estrogen biosynthesis, leading to lower proliferation rates 
in breast cancer cells subjected to ionizing radiation, apart from modulating angiogenesis through 
inhibition of pro-angiogenic factors (Alonso-González et al., 2020).  
Within the tumour microenvironment, melatonin may also modulate pre-adipocytes response to ionizing 
radiation (differentiation, aromatase activity and expression). Furthermore, the inhibition of glycolysis 
by melatonin in tumour cells also increases radiation response. In summary, all these findings position 
melatonin a potential adjuvant molecule for breast cancer treatment. Mainly because of its protective and 
sensitizing effects, increasing cellular response when administered in combination with conventional 













Melatonin is a pineal hormone with oncostatic properties that reduce the growth and development of 
hormone-dependent tumours, breast cancer included. More recently, melatonin has been considered as 
an adjuvant to chemotherapy or radiation, due to its ability to enhance the efficacy of these treatments. 
Therefore, the main objective of this work is to deepen into the molecular mechanisms involved and 
characterize the intracellular signaling pathways related to the sensitizing effects of melatonin to 
chemotherapy and radiotherapy using ER+ MCF-7 breast cancer cells as a model. In this regard, with this 
project we aim to complete the following specific objectives: 
 To study if melatonin is able to potentiate the anti-proliferative effects of radiation and 
chemotherapeutic agents (docetaxel and doxorubicin).  
 To analyse the changes induced by chemotherapy and ionizing radiation in the pattern of miRNA 
expression and to address the ability of melatonin to modulate those changes. 
 To characterize the changes induced by radiation in the phosphoproteome and to evaluate the role 
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MATERIALS AND METHODS 
  
Cell culture 
General condit ions 
Cell culture experiments were performed using MCF-7 cells, a non-metastatic and triple-positive breast 
tumour cell line purchased from the American Tissue Culture Collection (ATTC nº HTC-22™) 
(Rockville, MD, USA). These cells were cultured as monolayer in 75 cm2 plastic flasks in Dulbecco´s 
Modified Eagle´s Medium (DMEM) supplemented with 10% Fetal Bovine Serum (FBS), penicillin (20 
units/ml) and streptomycin (20 µg/ml) (all from Lonza, Switzerland) and incubated at 37 ºC with 5% CO2 
to maintain a humid atmosphere.  
 
Cell number determinat ion 
The total number of cells and their viability was determined using a Neubauer cell counting chamber. 
The full grid on the hemocytometer contains nine squares framed within an area of 1 mm2 (Figure 1). 
The central counting area of the hemocytometer contains 9 large squares with 16 smaller squares inside. 
For cell counting, the chamber is previously mounted by placing a coverslip on top of the slide, allowing 
the suspension to flow due to capillarity. After this, 20 µL of cell suspension were dispensed into the 
chamber. Cells were counted using a fluorescence microscope (NIKON TMS, Germany), considering 
cells situated inside the central and four corner squares. The formula showed in Figure 1 was used to 
calculate the number of cells present in the cell suspension. 
 
Reagents and treatments  
Two different chemotherapeutic drugs were used in the experiments carried out in this project: docetaxel 
and doxorubicin. On one hand, docetaxel (Sigma-Aldrich), is a taxane that binds and stabilizes the 
β−tubulin subunit of microtubules, preventing depolymerization of the mitotic spindle. On the other hand, 
doxorubicin (Sigma-Aldrich), is a cytotoxic anthracycline which intercalates within DNA base pairs, 
causing inhibition of both DNA and RNA synthesis. Both drugs were diluted in ethanol at a final  
Figure 1. Hemocytometer gridlines. Hemocytometer diagram indicates one of the sets of 16 squares used for counting. 
(#) indicates the number of squares counted. 
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concentration of 0.1 M (stock) and stored at -20 ºC. The final concentration in culture media was either 
1 µM or 1 nM, being the final concentration of ethanol lower than 0.0001%.  
Melatonin stock (Sigma-Aldrich) was diluted in ethanol as well, achieving a final concentration of 100 
mM, stored at -20 ºC. Melatonin used in culture media had a final concentration of 1 nM, a dose 
considered equivalent to the physiological concentration during night-time. 
Ionizing radiat ion 
MCF-7 cells were exposed to X-ray irradiation using YXLON SMART 200 tube (Yxlon International, 
Germany) at the Department of Radiology and Medical Physics of the University of Cantabria. Radiation 
was administered as an only-dose in a 11.5 cm x 8.5 cm field size. The source-half-depth distance was 
initially calculated to obtain a constant dose rate of 0.92 Gy/min. The radiation dose used was 8 Gy as 
previously described in our laboratory (Alonso-González, 2015).  
Cell Proliferation assay 
MCF-7 cells at 70-80% of confluency were initially cultured for 24 hours in DMEM supplemented with 
0.5% dextran-charcoal stripped FBS (csFBS) and incubated at 37 ºC for 24 hours to allow cellular 
attachment. Melatonin pre-treated cells were incubated for 7 days in DMEM supplemented with 10% 
FBS containing 1 nM melatonin before being seeded into 96-multiwell plates. Cells were seeded at a 
density of 8 x 103 cells per well and 24 h later, melatonin pre-treated and control MCF-7 culture plates 
were irradiated at a dose of 8 Gy. Control cells were removed from the incubator and placed for the same 
period of time into the irradiator but without receiving any radiation.   
Regarding chemotherapy studies, the procedure was the same as the described above. When cells were 
treated with chemotherapeutic agents, docetaxel and doxorubicin, both compounds were diluted in the 
culture media to achieve a final concentration of 1 nM.  
In all cases, cells were incubated for 6 days and after that time, cell proliferation was measured by the 
MTT [3(4,5dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] method. MTT (Sigma-Aldrich) is a 
yellow reagent that is reduced to purple formazan in the mitochondria of living cells. This reduction takes 
place only when mitochondrial reductase enzymes are active. Therefore, conversion can be directly 
related to the number of viable cells. MTT was dissolved in Phosphate Buffer Saline (PBS) at a dose of 
1 mg/mL and added 100 μL of the mixture to each well. It is important to conduct this step avoiding light 
exposure. Plates were incubated at 37 ºC for 4 h to allow formation of formazan crystals. Then, crystals 
were dissolved by adding a solution of 1 g of Sodium Dodecyl Sulphate (SDS, Pancreac AppliChem, 
USA) in 10 mL of HCl. After a 24 h incubation period, cell proliferation was determined by measuring 
absorbance levels at 570 nm using a microplate reader spectrophotometer (Labsystems MultiSkan RC 
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351, USA), assuming that an increase in cell number is directly related to the increase in absorbance due 
to the amount of MTT formazan formed. 
Total RNA extraction 
As previously described, MCF-7 cell cultures were pre-treated with melatonin 1 nM for 1 week before 
seeding. Later, cells were seeded into 6-well plates at a density of 1 x 106 cells per well in DMEM 
supplemented with 10% FBS. The following day, plates were either irradiated at 8 Gy or treated with 
chemotherapeutic agents (docetaxel or doxorubicin) at a dose of 1 µM. After a 4 h incubation step, total 
cellular RNA, including miRNA and other small RNA molecules, was isolated using the miRNeasy RNA 
kit (Qiagen, USA) following the manufacturer’s instructions (Figure 2).   
First, 700 µL of QIAzol lysis reagent were added to each well to homogenize the samples, using scrapers 
to scratch the well’s base. Then, the homogenate was incubated at room temperature for 5 min. After 
chloroform addition, the homogenate was separated into three phases by a centrifugation step at 12000 
g. The upper aqueous phase was transferred to a new collection tube containing 1.5 volumes of ethanol 
100%, thus providing optimal conditions to bind RNA molecules to the affinity column. The mixture is 
then added to the RNeasy spin column and centrifuged at 9000 g at room temperature for 15 s, providing 
that RNA binds to the membrane. After washing with buffer RPE to eliminate other contaminants, RNA 
was eluted by adding 40 µL of RNase-free water into the column. The quality and quantity of the RNA 
eluted were measured with a spectrophotometer (Nanodrop 1000 V 3.6). The ratio A260/A280 was used to 
asses RNA purity, considering samples with a ratio between 1.9-2.0 as pure RNA.  
Conversion of mature miRNA into cDNA 
In order to perform miRNA expression analysis, RNA samples were polyadenylated by poly(A) 
polymerase and subsequently converted into cDNA by a reverse transcription reaction using miScript II 
RT Kit (Qiagen, USA) (Figure 3). Both steps were performed in parallel in the same tube, using and 
oligo-dT primer with universal tag sequence on the 5’ end, allowing amplification of mature miRNA in 
the qPCR analysis. For cDNA synthesis, 250 ng of total RNA were mixed with the different components 
according to the manufacturer’s instructions (shown in Table 1). Each reaction was incubated in a 
thermocycler (MyCycler Gradient, Bio-Rad, USA). The protocol followed a two-step reaction: 60 min at 
Figure 2. Total RNA extraction procedure (including miRNA) using miRNeasy RNA kit (Qiagen, USA).  
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37 ºC and 5 min at 95 ºC to inactivate reverse transcriptase activity. Finally, each sample was diluted in 
200 µL of RNase-free water and stored at -20 ºC until use. 
 
Table 1. cDNA synthesis reagents and correspondent volumes. Volumes are expressed in (µL). 
Component Volume  
miScript HiSpec Buffer 4 
miScript Nucleics Mix 2 
RNase-free water Variable 
miScript Reverse Transcriptase Mix 2 
Template RNA Variable 
Total volume 20 
 
Breast Cancer Pathway-Focused miRNA PCR array 
To study changes in miRNAs expression through different treatments, a pathway focused miRNA 
expression profiling was performed using a Human Breast Cancer microarray (MIHS-109ZA, Qiagen, 
USA). Specifically, this array consists of 84 mature miRNA forward primers arrayed in miRNome panels, 
that appear to be somehow related to breast cancer. Each well contains the components required to ensure 
that each quantitative PCR reaction (qPCR) will generate a single, gene-specific amplicon, preventing 
the co-amplification of non-specific products. The array also contains miScript PCR controls that enable 
normalization: an array normalizer (C. elegans miR-39), six normalization controls (SNORD61, 
SNORD68, SNORD72, SNORD95, SNORD96A, RNU6B/RNU6-2), a reverse transcription control 
(miRTC) and a positive PCR control (PPC), as shown in Figure 4.  
Figure 3. cDNA synthesis procedure by using miScript RT II kit (Qiagen, USA).  





Real-t ime PCR for miRNA PCR Array 
The PCR array performs miRNA expression analysis with qPCR sensitivity and the multi-gene profiling 
capability of a microarray. The cDNA obtained from RNA extraction samples was mixed with the 
reagents provided by the miScript SYBR Green PCR Kit (Qiagen, USA), as shown in Table 2. This 
Master mix contains a miScript universal primer as a reverse primer that allows the detection of mature 
miRNAs in combination with miScript specific primers attached to the array plate wells (forward primer) 
(Figure 5). For the 96-well plate, 25 µL of master mix were dispensed to each well. To avoid the presence 
of bubbles, plates were centrifuged at 1000 g at room temperature for 1 min. Afterwards, plates were 
placed in a qPCR thermocycler (CFX96 Bio-Rad, USA) using the following protocol: an initial activation 
step of 15 min 95 ºC with a ramp rate of 1º C/s and a three-step cycling based on a denaturation step (15 
s; 94 ºC), an annealing step (30 s; 55 ºC) and an extension step (30 s; 70 ºC). Cycling step was repeated 
40 times. Melting curves were plotted after the final cycling step to verify unspecific amplification of 
primers.  
 
1 hsa-let-7a-5p 9 hsa-miR-1-3p 17 hsa-miR-129-5p 25 hsa-miR-152-3p 33 hsa-miR-181c-5p 59 hsa-miR-222-3p
2 hsa-let-7b-5p 10 hsa-miR-100-5p 18 hsa-miR-130a-3p 26 hsa-miR-155-5p 34 hsa-miR-181d-5p 60 hsa-miR-223-3p
3 hsa-let-7c-5p 11 hsa-miR-107 19 hsa-miR-130b-3p 27 hsa-miR-15a-5p 35 hsa-miR-182-5p 61 hsa-miR-25-3p
4 hsa-let-7d-5p 12 hsa-miR-10a-5p 20 hsa-miR-132-3p 28 hsa-miR-15b-5p 36 hsa-miR-186-5p 62 hsa-miR-26a-5p
5 hsa-let-7e-5p 13 hsa-miR-10b-5p 21 hsa-miR-140-5p 29 hsa-miR-16-5p 37 hsa-miR-18a-5p 63 hsa-miR-26b-5p
6 hsa-let-7f-5p 14 hsa-miR-125b-5p 22 hsa-miR-141-3p 30 hsa-miR-17-5p 38 hsa-miR-193b-3p 64 hsa-miR-27a-3p
7 hsa-let-7g-5p 15 hsa-miR-125b-1-3p 23 hsa-miR-145-5p 31 hsa-miR-181a-5p 39 hsa-miR-195-5p 65 hsa-miR-27b-3p
8 hsa-let-7i-5p 16 hsa-miR-128-3p 24 hsa-miR-148a-3p 32 hsa-miR-181b-5p 40 hsa-miR-199b-3p 66 hsa-miR-29a-3p
41 hsa-miR-199a-5p 67 hsa-miR-29b-3p
42 hsa-miR-19a-3p 68 hsa-miR-29c-3p
43 hsa-miR-19b-3p 69 hsa-miR-31-5p
44 hsa-miR-200a-3p 70 hsa-miR-328-3p
45 hsa-miR-200b-3p 71 hsa-miR-340-5p
46 hsa-miR-200c-3p 72 hsa-miR-424-5p
47 hsa-miR-202-3p 73 hsa-miR-429
48 hsa-miR-203a-3p 74 hsa-miR-485-5p
49 hsa-miR-204-5p 75 hsa-miR-489-3p
50 hsa-miR-205-5p 76 hsa-miR-495-3p
51 hsa-miR-206 77 hsa-miR-497-5p
52 hsa-miR-20a-5p 78 hsa-miR-548c-3p
53 hsa-miR-20b-5p 79 hsa-miR-607
54 hsa-miR-21-5p 80 hsa-miR-613
55 hsa-miR-210-3p 81 hsa-miR-7-5p
56 hsa-miR-212-3p 82 hsa-miR-93-5p
57 hsa-miR-214-3p 83 hsa-miR-96-5p
58 hsa-miR-22-3p 84 hsa-miR-98-5p
Figure 4. MIHS-109ZA Human Breast Cancer microarray scheme for 96-well plates. Wells A1 to G12 contain 
selected miRNAs related to breast cancer (listed on the top-right tables). Wells H3 to H8 each contain an assay for a 
different snoRNA/snRNA that can be used as a normalization control for the array data. Wells H1 and H2 contain 
replicate C. elegans miR-39 can be used as an alternative normalizer for array data (Ce). Wells H9 and H10 contain 
replicate reverse transcription controls (miRTC). Wells H11 and H12 contain replicate positive PCR controls (PPC). 
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Table 2. PCR synthesis reagents and correspondent volumes. Volumes are expressed in (µL) and calculated for the total of a 
96-well plate, adding 25 µL per well. 
Component Volume  
QuantiTect SYBR Green PCR Master Mix 1375 
miScript Universal Primer 275 
RNase-free water 1000 
Template cDNA 100 
Total volume 2750 
 
 
Data obtained by qPCR were analyzed using Qiagen GeneGlobe online tool for microarray data 
management. CT values were exported from the original qPCR software and transcribed into GeneGlobe 
Analyze section, obtaining fold change data (based on ΔΔCT method), sample quality assessments and 
different plots. This information was used for miRNA selection between different experimental groups 
to perform specific qPCRs.  
 
Figure 5. miScript PCR microarray procedure by using MIHS-109ZA Human Breast 
Cancer microarray (Qiagen, USA).  
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Analysis of specific miRNAs by qPCR 
Selected miRNAs from the PCR microarray were subjected to specific qPCR to further validate their 
expression profiles. RNA extraction samples were used to obtain cDNA by a reverse transcriptase 
reaction. Complementary DNA samples were mixed with the reagents provided by the miScript Primer 
Assays Kit (Qiagen, USA), as shown in Table 3. RNase-free water was added to the mix in order to 
complete the total volume of 25 µL/per well. SNORD68 and SNORD95 were used as normalization 
controls. Specific miRNAs selected were: miR-20a, miR-20b, miR-17, miR-141, miR-15a, miR-19a, 
miR-29a and miR-93. To avoid bubbles during qPCR plate lecture, plates were centrifuged at 1000 g at 
room temperature for 1 min. Afterwards, plates were placed in a PCR thermocycler (CFX96 Bio-Rad, 
USA) using the following protocol: an initial activation step of 15 min 95 ºC and a three-step cycling 
based on a denaturation step (15 s; 94 ºC), an annealing step (30 s; 55 ºC) and an extension step (30 s; 70 
ºC), repeating the cycling step 40 times. Melting curves were plotted after the extension step of each cycle 
to verify unspecific amplification of primers.  
Table 3. PCR synthesis reagents and correspondent volumes. Volumes are expressed in (µL). 
Component Volume  
QuantiTect SYBR Green PCR Master Mix 12.5 
miScript Universal Primer 2.5 
miScript Specific Primer 2.5 
RNase-free water 5 
Template cDNA 2.5 
Total volume 25 
 
qPCR Data analysis 
 
The ΔΔCT method is the recommended data analysis tool for qPCR experiments. CT values obtained for 
the normalization miRNAs primers (HKG) and miRNAs of interest (GOI) were determined in each 
sample. It is important to note that only CT values less than 35 were used for the analysis. For each set of 
samples, the difference in ΔCT values (ΔΔCT) for the miRNAs of interest between the samples was 
calculated. Specifically, the difference between the CT values (ΔCT) for each miRNA of interest and the 
average CT value of the set of housekeeping miRNAs were calculated as follows: 
ΔCT (control) = CT (GOI) – CT (HKG) 
ΔCT (experimental) = CT (GOI) – CT (HKG)  
The difference in ΔCT values (ΔΔCT) between the two samples were calculated as: 
ΔΔCT = ΔCT (experimental) – ΔCT (control)  
Finally, the fold-change for each gene between the control group and the different treatments was 
calculated as 2(-ΔΔCT). 
Phosphokinase screening 
To determine the sensitizing effects of melatonin in radiation-induced changes in multiple kinases and 
their protein substrates we used a membrane-based sandwich immunoassay Human Phospho-Kinase 
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Array Proteome ProfilerTM (R&D Systems, USA). This array allows the simultaneous detection of 
relative phosphorylation levels of 37 kinases. In particular, the membrane allows the antibodies to bind 
to specific target proteins present in our samples.  
This study was performed on MCF-7 cells cultured in DMEM medium supplemented with 10% FBS and 
treated with radiation (8 Gy) either pre-treated or not with melatonin (1 nM). Cells were seeded into 6-
well plates at a cellular density of 8 x105 cells per well. After a 4 h incubation, cells were washed twice 
with chilled PBS, lysed and mixed for 30 minutes in a rocking platform at 4 ºC. Cell lysates (containing 
500 µg of protein) were then added to the previously blocked nitrocellulose membranes and incubated 
overnight at 2-8 °C on a rocking platform. After performing two PBS washes, antibody detection cocktails 
were added to the membranes and incubated for 2 h at room temperature. Once the incubation step was 
finished, streptavidin-HRP-conjugated secondary antibodies were used for chemiluminescent detection, 
generating a signal directly proportional to the amount of protein bound to the membrane. Finally, the 
membranes were exposed to a film using a chemical reagent mix with hydrogen peroxide and luminol. 
Pixel densities on the X-ray film were collected and analyzed using a LI-COR Odyssey IR Imaging 
System V3.0 (LI-COR Odyssey Biosciences, USA).  
Analysis of protein levels 
Protein extract ion 
Western Blot analysis was used to further validate the most relevant changes observed in the 
phosphokinase assay, which included Akt, p70S6 kinase and their active phosphorylated versions in 
residues Thr308 for p-Akt and Thr389 for p-p70S6. MCF-7 control and melatonin pre-treated cells were 
seeded and irradiated as described above, performing protein extraction after a 4 h incubation period. For 
that purpose, each well was washed twice with 1 mL of chilled PBS. Then cells were lysed by adding 0,5 
mL of RIPA buffer per well, containing phosphatase inhibitors (1:100) and protease inhibitors (1:250). 
To facilitate protein lysis, the well’s base was scratched using scrapers. Samples were placed in a 2 mL 
Eppendorf and stored at -20 ºC.  
Protein concentration was assessed by Bradford colorimetric method in a spectrophotometer at 620 nm 
wavelength. Briefly, Bradford method is based on the bond between Coomassie Blue dye and the proteins 
of interest, specifically binding to the blue form of this dye. This protein-colorant complex has a higher 
molar extinction coefficient than free colorant, allowing protein detection. After this, a standard curve 
was generated using Bovine Serum Albumin (BSA, Sigma-Aldrich, USA). Hereinafter, samples were 
mixed at a 1:1 ratio with a mix of Laemmli and β-mercaptoethanol 5% (Bio-Rad, USA) using a vortex. 
Afterwards, the mix was heated at 98 ºC in a dry-bath for 10 min. A centrifugation step was performed 
at 14000 g at 4 ºC for 5 min. Supernatant was isolated from the samples and stored at -70 ºC until use.  
 




To perform electrophoresis, 25 µg of each protein sample were loaded to a 10% SDS-PAGE gel (SDS-
polyacrylamide), using 3 µL of NZYBlue (NZYtech, Portugal) molecular weight marker as a reference. 
SDS-PAGE gels were done prior to electrophoresis procedure, using the following components (Table 
4): 
Table 4. Electrophoresis gel components and volumes. Volumes are expressed in mL. Resolving buffer was done by mixing 
90.85 g of Tris in 20 mL of SDS 10 % adding HCl until reaching a pH of 8.8. Stacking buffer was done by mixing 30.3 g Tris in 
20 mL of SDS 10 % adding HCl to adjust pH to 6.8. 
 Volume 
Component Resolving gel Stacking gel 
Distilled water 5 1.562 
Acrylamide/Bis-acrylamide 40 % 2.5 0.313 
Resolving buffer (pH 8,8) 2.5 - 
Stacking buffer (pH 6,8) - 0.625 
Ammonium persulfate (APS) 10 % 0.150 0.042 
Temed 0.0075 0.0075 
 
The gel was placed in an electrophoresis tank loaded with migration buffer 1X (Tris 25 mM pH 8.5; 
glycine 0.2 M; SDS 0.1%). A constant voltage of 100 V was applied to the tank for 15 min until the 
electrophoresis front reached the resolving gel. Afterwards, a constant voltage of 160 V was applied for 
50 min.  
After this, gels were removed from the gel cassette and immersed in transference buffer (Tris 25 mM pH 
8.3; glycine 192 mM; methanol 20%) for 30 min in a rocking platform. Immediately after, the 
transference sandwich was assembled. In each cassette, gel and the polyvinylidene difluoride (PVDF) 
membranes (Bio-Rad, USA) are put in tight contact and surrounded by filter paper and fibber pads, all 
soaked in transference buffer. Transference cassettes were placed in a transference tank loaded with 
chilled transference buffer and subjected to a constant voltage of 100 V at 4 ºC for 100 min. Protein 
transference efficacy was assessed by membrane staining with Ponceau S red and gel staining with 
Coomassie Blue.  
For membrane blockage, a solution of BSA 3% in TBS-T (Tris-HCl 10 mM, pH 7.6, NaCl 150 mM, 
Tween 20 0.05%) was added to the membranes, letting it sit for 1 h at room temperature. This avoids 
unspecific binding of primary antibodies. The following step was incubating the membranes with the 
selected primary antibody diluted in blocking solution at 4 ºC overnight in a rotary shaker. Afterwards, 
three washing steps of 10 min using TBS-T were performed in a rocking platform. Later on, membranes 
were incubated with a secondary antibody with a fluorescent dye diluted in blocking solution for 1 h at 
room temperature. After incubation, three washing steps, following the aforementioned conditions, were 
done. Selected antibodies description is shown in Table 5.  
To correct differences while loading samples in the gel, membranes were incubated with actin antibody 
for 24 h at 4 ºC, serving as a normalizing control. Fluorescence signal was detected using LI-COR 
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Odyssey IR Imaging System V3.0 (LI-COR Odyssey Biosciences, USA). To study differences in optical 
density bands, we used Image Studio and ImageJ software. Three different protein extracts were analysed 
and data were represented as percentage of control (non-treated cells).  
 
Table 5. Antibody specifications.  
 




Akt (pan) (Cell Signalling, USA) 1:250 Monoclonal/Rabbit 60 
Phospho-Akt (Thr 308) (Cell Signalling, USA) 1:250 Monoclonal/Rabbit 60 
p70S6 Kinase (Thr 389) (Cell Signalling, USA) 1:250 Monoclonal/Rabbit 70,85 
Phospho-p70S6 Kinase (Cell Signalling, USA) 1:250 Policlonal/Rabbit 70,85 
Actin  1:1000 Monoclonal/Mouse 42 
Secondary 










Results are expressed as mean ± standard error of mean (SEM) from three independent experiments. 
Statistical differences between groups were processed by One Way Analysis of Variance (ANOVA) 
followed by the Student-Newman-Keuls test, with p <0.05, p<0.01 and p<0.001 considered to be 
statistically significant.  
Image Studio 5.2 and ImageJ software were used for protein analysis, CFX Maestro 2.0 and Qiagen 

























Radiation and melatonin 
Effects of ionizing radiat ion and melatonin on MCF-7 cell proliferat ion  
The first objective of this work was to corroborate the oncostatic properties of melatonin on MCF-7 cell 
proliferation, as well its ability to enhance the anti-proliferative effect of radiation. Previous results from 
our laboratory had established 8 Gy as the optimal radiation dose for MCF-7 cells. As shown in Figure 
1, with radiation alone the inhibition of cell proliferation was 45% and 33% after 3 (Figure 1A) and 6 
days (Figure 1B) of incubation after irradiation. Finally, the greatest inhibition on cell proliferation was 
found when cells were pre-treated with the indolamine before being radiated, showing a reduction of 58% 
after 3 days and 62% after 6 days when compared to non-radiated cells.  
 
Effects of ionizing radiat ion and melatonin on the expression of breast cancer-
related miRNAs 
To study the effects of melatonin and radiation on miRNA expression patterns in MCF-7 cells, we 
employed a Human Breast Cancer microarray (MIHS-109ZA, Qiagen, USA). This array contains 84 
mature miRNA that appear to be somehow related to breast cancer. Establishing a fold-change of  ± 2, 
melatonin pre-treatment showed a downregulation of 27 miRNAs and an upregulation of 6 miRNAs when 
compared to control cells (Figure 2A). In a similar way, radiation alone modified the expresion of 33 
miRNAs (29 downregulated and 4 upregulated) as we can see in the heatmap showed in Figure 2B. 
Finally, the most significant results in fold-change analysis were observed in those cells that were pre-
treated with melatonin for one week before being irradiated. In this case, 37 miRNAs were downregulated 
and 6 upregulated compared to non-radiated control cells (Figure 2C).  
Figure 1. Effect of melatonin pre-treatment and ionizing radiation on MCF-7 cell proliferation. Cells were pre-treated with 
melatonin 1 nM for one week, radiated at 8 Gy or a combination of both treatments. Cell proliferation was measured at 3 (A) 
or 6 (B) days after radiation. Data are expressed as percentage of control non-radiated cells (mean ± SEM). a, p<0.01 vs. C; 
b, p<0.001 vs. C; c, p<0.001 vs. CR. C: Control; M: 1 nM melatonin pre-treated cells; CR: Radiated cells (8 Gy); MR: 
Melatonin pre-treated and radiated cells.   
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It is important to specify that the membranes included in the miRNA microarray contain only one well 
for each of the miRNAs analyzed. Therefore, the results showed in Figure 2 may serve as a preliminar 
study of what may be happening with each of the treatments analyzed in this work. Thus, these results 
must be confirmed by specific qPCR. For this project, due to their relevance in breast cancer onset and 
progression, a set of 8 miRNAs (miR-20a, miR-20b, miR-17, miR-141, miR-15a, miR-19a, miR-29a and 
miR-93), were selected to be studied specifically. The relative quantity (Δ CT) of these specific miRNAs 
is shown in Figure 2D. 
 
Results of microarray miRNA profiles were further validated by specific qPCR. When MCF-7 cells were 
pre-treated with 1 nM of melatonin, the indolamine significantly decreased the expression levels of miRs 
20a, 20b, 19a, 29a and 93 in comparison to control cells. Similar results were found when cells were 
irradiated. Surprisingly, radiation treatment resulted in a significant overexpression of miRs 17, 141 and 
15a. Nevertheless, when cells were treated with melatonin prior to radiation, this hormone was able to 





Figure 2. Effects of melatonin and radiation on breast cancer miRNAs expression microarray. Cells were pre-treated with 
melatonin (1 nM) for one week and/or radiated (8 Gy). Total RNA was extracted after 4 h, reverse transcribed and used for qPCR 
analysis using Human Breast Cancer microarray (MIHS-109ZA). Panels A-C show heatmaps of relative normalized expression 
between different treatments (A) M vs C; (B) CR vs C; (C) MR vs C. (D) Bar chat of relative normalized expression (ΔCT) of 
selected miRNAs. a: miR20a; b: miR-20b; c: miR-17; d: miR-141; e: miR-15a; f: miR-19a; g: miR29a; h: miR-93. C: Control; 
M: Melatonin pre-treated cells; CR: Radiated cells; MR: Melatonin pre-treated and radiated cells.   
D 
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Changes on kinase intracellular regulators induced by melatonin and radiat ion  
To study the modulatory effects of melatonin in different signaling pathways related with cell 
proliferation and survival, we investigated the changes in the activation or inactivation status of different 
protein kinases, using the Proteome ProfilerTM Array (R&D Systems, USA). As shown in Figure 4A, the 
most relevant results from the array panels were found in two proteins belonging to the mTOR signaling 
pathway: Akt (Thr308), which phosphorylates mTOR directly; and the ribosomal protein p70S6 kinase 
(Thr389), one of the downstream substrates of mTORC1, leading to cell survival and proliferation when 
activated. Radiation alone induced a reduction on the relative phosphorylation levels of both proteins 
compared to control cells. These inhibitory effects were also potentiated when cells were pre-treated with 
melatonin prior to radiation (Figure 4B).  
 
 
Figure 3. qPCR analysis of the specific miRNAs expression levels in MCF-7 cells. Cells were treated with 1 nM melatonin 
and/or irradiated (8 Gy), and after 4 h total RNA was isolated and reverse transcribed. cDNA was subjected to qPCR using 
miRNA specific primers. Data are expressed as a relative normalized expression compared to control cells (mean ± SEM). a, 
p<0.001 vs. C; b, p<0.05 vs. C; c, p<0.01 vs. C; d, p<0.01 vs. CR; e, p<0.05 vs. CR; f, p<0.001 vs. CR. C: Control; M: 1 nM 
melatonin pre-treated cells; CR: Radiated cells (8 Gy); MR: Melatonin pre-treated and radiated cells.   




To validate this data, we performed protein quantification studies in the different samples by western blot 
(Figure 5). In these experiments, a group of melatonin pre-treatment was also included to see specifical 
differences that were not determined in the phosphokinase assay. Surprisingly, radiation induced a 
significant increase in total Akt levels compared to control non-treated cells. In spite of this, melatonin 
pre-treatment was able to counteract this radiation effect (Figure 5A). In respect of Akt phosphorylated 
version (p-Akt), neither radiation nor melatonin modified its expression. Nevertheless, melatonin-pre-
treatment prior to radiation showed a significant decrease in Akt activation compared to control cells 
(Figure 5B). 
Regarding p70S6K, radiation slightly increased its total protein levels but once again this effect was 
counteracted by melatonin (Figure 5C). However, none of the treatments were able to induce significant 






Figure 4. Effects of melatonin and radiation on the phosphorylation levels of Akt and p70S6 kinases. (A) Representative 
images of Proteome Profiler array blots assessed with protein extracts from MCF-7cells pre-treated with melatonin and/or 
radiated (8 Gy). Dots corresponding to Akt levels are shown in yellow and p70S6K dots are shown in red. (B) Bar chart 
compiling quantification densitometry data of Akt dots, expressed as percentage of control. (C) Bar chart compiling 
quantification data of p70S6K, expressed as percentage of control. C: Control; CR: Radiated cells (8 Gy); MR: Melatonin 
pre-treated (1 nM) and radiated cells.  
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Chemotherapy and melatonin 
Effects of chemotherapeut ic agents and melatonin on MCF-7 cell proliferat ion  
Another point of this work was to address whether melatonin could sensitize MCF-7 cells to 
chemotherapeutic agents (docetaxel and doxorubicin). To illustrate this, cell proliferation experiments 
were conducted, showed in Figure 6 and Figure 7.  
We first wanted to determine the effects of different docetaxel doses on MCF-7 cell proliferation. As 
expected, docetaxel inhibited cell proliferation in a dose dependent manner (Figure 6A) after 6 days of 
incubation. Based on these results, we selected sub-pharmacological doses of docetaxel (1 nM) to test the 
ability of melatonin to potentiates docetaxel effect. As we can see on Figure 6B, melatonin pre-treatment 
at physiological concentrations (1 nM) potentiates the docetaxel-induced growth inhibition, leading to an 
inhibition of 75% compared to control cells.  
Figure 5. Effects of melatonin and radiation on total and phosphorylated Akt and p70S6 kinases. Protein extracts from 
MCF-7 cells treated with 1 nM of melatonin, radiation (8Gy) or both were used for Western-Blot detection of total Akt (A), p-
Akt (Thr308) (B), total p70S6K (C) and p-p70S6K (Thr389) (D). Bar chart data are expressed as % of control non-radiated 
cells, using β-actin as a loading control. a, p<0.05 vs. C; b, p<0.001 vs. C; c, p<0.001 vs. CR. C: Control; M: 1 nM melatonin 
pre-treated cells; CR: Radiated cells (8 Gy); MR: Melatonin pre-treated and radiated cells.   












The other chemotherapeutic agent used in this work was doxorubicin. Similarly to the taxane, doxorubicin 
inhibited MCF-7 cell proliferation at different doses, showing the greatest inhibition at doses over 100 
nM (Figure 7A). Once again, melatonin exerts its well-known anti-proliferative actions decreasing cell 
proliferation. When this hormone was combined with the anthracycline, both compounds potentiate their 
anti-proliferative effects, reaching the greatest inhibition (88%) compared with non-treated control cells 


























Effects of chemotherapeut ic agents and melatonin on the expression of breast  
cancer-related miRNAs 
To evaluate the effects of melatonin and chemotherapeutic agents in miRNA expression patterns in breast 
cancer cells we used the same Human Breast Cancer microarray tecnhnology previously mentioned. In 
this case, the chemotherapeutic agents were used at higher doses (1 µM) since the treatments were 
maintained only for 4 hours.  
Figure 6. Effect of melatonin pre-treatment and docetaxel on MCF-7 cell proliferation. (A) Cell proliferation measured at 
different docetaxel doses ranging from 1000 to 0.01 nM after 6 days of incubation (B) Effects of melatonin-pre-treatment and/or 
docetaxel (1 nM) on cell proliferation after 6 days of culture. Data are expressed as percentage of control cells (mean ± SEM).  
a, p<0.001 vs. C; b, p<0.01 vs. C; c, p<0.001 vs. Doc. C: Control, M: 1 nM melatonin pre-treated cells, Doc: 1 nM Docetaxel, 
MDoc: Melatonin and docetaxel. 
Figure 7. Effect of melatonin pre-treatment and doxorubicin on MCF-7 cell proliferation. (A) Cell proliferation measured at 
different doxorubicin doses ranging from 1000 to 0.01 nM after 6 days of incubation. (B) Effects of melatonin-pre-treatment 
and/or doxorubicin (1 nM) on cell proliferation after 6 days of culture. Data are expressed as percentage of control cells (mean 
± SEM). a, p<0.001 vs. C; b, p<0.01 vs. C; c, p<0.001 vs. Doxo. C: Control; M: 1 nM melatonin pre-treated cells; Doxo: 1 nM 
Doxorrubicin; MDoxo: Melatonin and doxorubicin. 
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Establishing a fold-change of  ±2, melatonin pre-treatment showed a downregulation of 26 miRNAs and 
an upregulation of 7 miRNAs when compared to control cells (Figure 8A). When docetaxel was 
administered alone, the expresion of 39 miRNAs (32 downregulated and 7 upregulated) was modified as 
displayed in Figure 8B. Finally, when both treatments were combined, 8 miRNAs were downregulated 
and 2 upregulated compared to control cells (Figure 8C). Relative quantity (Δ CT) of selected miRNAs 





































Results extracted from the microarray profiles were further validated by specific qPCR. When MCF-7 
cells were pre-treated with 1 nM of melatonin, miRNA expression levels generally decreased, except 
from miR-93, miR-29a, miR-19a and miR-15a.  Similar results were found when cells were treated with 
docetaxel, reducing the expression of miR-20a, miR-20b and miR-17. On one hand, addition of melatonin 
before the taxane was able to potentiate docetaxel effect on miR-20a and miR-20b. On the other hand, 
docetaxel administration significantly induced the expression of miR-141, miR-15a and miR-19a. 
However, when cells were treated with melatonin prior to docetaxel, this hormone was able to counteract 




Figure 8. Effects of melatonin and docetaxel on breast cancer miRNAs expression microarray. Cells were pre-treated with 
melatonin (1 nM) for one week and/or docetaxel (1 µM). After 4h, total RNA was extracted, reverse transcribed and used for 
qPCR analysis using miRNA Human Breast Cancer microarray (MIHS-109ZA). Panels A-C show heatmaps of relative 
normalized expression between different treatments (A) M vs C; (B) Doc vs C; (C) MDoc vs C. (D) Relative quantity (∆CT) of 
selected miRNAs bar chart. a: miR20a; b: miR-20b; c: miR-17; d: miR-141; e: miR-15a; f: miR-19a; g: miR29a; h: miR-93. C: 
Control; M: 1 nM melatonin pre-treated cells; Doc: Docetaxel (1 µM); MDoc: Melatonin pre-treated and docetaxel. 
 




Finally, we tested the effect of melatonin on miRNA expression changes induced by doxorubicin in MCF-
7 cells. The most important changes were observed when the anthracyclin was added alone to the culture 
media, inducing a downregulation of 40 miRNAs and an upregulation of 6 miRNAs (Figure 10B). When 
cells were pre-treated with melatonin for one week before doxorubicin administration, only 17 miRNAs 
were modified (13 were downregulated and 4 upregulated) compared to non-radiated control cells 
(Figure 10C). Relative quantity (Δ CT) of selected miRNAs from previous experiments of this work was 











Figure 9. qPCR analysis of the specific miRNAs relative levels in MCF-7 cells. Cells were treated with 1 nM melatonin 
and/or docetaxel (1µM), and after 4 h total RNA was isolated and reverse transcribed. cDNA was subjected to qPCR using 
miRNA specific primers. Data are expressed as a relative normalized expression compared to control cells (mean ± SEM). a, 
p<0.01 vs. C; b, p<0.001 vs. C; c, p<0.05 vs. Doc; d, p<0.01 vs. Doc. C: Control; M: 1 nM melatonin pre-treated cells; Doc: 
Docetaxel (1 µM); MDoc: Melatonin pre-treated and docetaxel. 
 















































Figure 10. Effects of melatonin and doxorubicin on breast cancer miRNAs expression microarray. Cells were pre-treated with 
melatonin (1 nM) for one week and/or doxorubicin (1 µM). After 4h, total RNA was extracted, reverse transcribed and used for 
qPCR analysis using miRNA Human Breast Cancer microarray (MIHS-109ZA). Panels A-C show heatmaps of relative normalized 
expression between different treatments (A) M vs C; (B) Doxo vs C; (C) MDoxo vs C. (D) Relative quantity (∆CT) of selected 
miRNAs bar chart. a: miR20a; b: miR-20b; c: miR-17; d: miR-141; e: miR-15a; f: miR-19a; g: miR29a; h: miR-93. C: Control; 





Potential of melatonin as an adjuvant molecule for radiotherapy treatment  
In hormonal-dependent breast cancer, endocrine therapy is often combined with radiotherapy in order to 
improve the tumour response to breast cancer treatment (Zhong et al., 2013). Besides, pre-clinical models 
have shown that combination of aromatase inhibitors with radiation can enhance cytotoxicity and tumour 
cell death (Azria et al., 2004).  
Melatonin, the main product of the pineal gland, has been widely reported as an anti-tumoral and anti-
aromatase hormone both in vivo and in vitro (Martínez-Campa et al., 2017). Moreover, this indolamine 
has been related with radioprotective and radiosensitising properties trough modulation of enzymes 
involved in estrogen biosynthesis, inhibition of cell proliferation through p53 upregulation, modulation 
of DNA repair mechanisms or induction of cell-cycle arrest and apoptosis (Alonso-González et al., 2020; 
Griffin & Marignol, 2018). Furthermore, melatonin exerts anti-angiogenic actions and neutralize 
proangiogenic effects induced by ionizing radiation (González-González et al., 2019). In summary, all 
these properties point at this indolamine as a promising agent to be used as an adjuvant to breast cancer 
conventional treatments.  
Irradiation of mammary glands induces changes that lead to the reduction of cell proliferation, proving 
its effectiveness as a breast cancer treatment (González-González et al., 2019). As supported in our 
project, literature indicates that radiation inhibits cell proliferation on MCF-7 cells (Kong et al., 2020; 
Alonso-González et al., 2015). Initially, in this work we wanted to evaluate the capability of melatonin 
to sensitize MCF-7 breast cancer cells to ionizing radiation. Hence, MCF-7 cells pre-treated with 
melatonin at physiological concentrations prior to radiation showed a significant reduction on cell 
proliferation, enhancing the anti-proliferative effects of ionizing radiation.  
Furthermore, melatonin relationship with breast cancer does not only involve cell proliferation but many 
other pathological processes impacting cell adhesion, migration, invasion and apoptosis, among others. 
Recent knowledge has attributed some of these effects to melatonin’s interaction with microRNAs (Kong 
et al., 2020; Farhood et al., 2019). MicroRNAs, known as miRNAs, are small non-coding molecules that 
take part in several cellular pathways, some of them with biological relevance for breast cancer. Many 
literature has reported melatonin’s capability of altering transcription factors, kinases, tumour suppressor 
genes and oncogenes via differential expression of miRNAs (Chuffa et al., 2020).  
To study the effects of melatonin and radiation on miRNAs expression patterns in MCF-7 cells, we used 
a miRNA Human Breast Cancer microarray (MIHS-109ZA, Qiagen, USA) that contains 84 mature 
miRNA whose expression is known to be altered in breast cancer. When cells were pre-treated for one 
week with melatonin at physiological concentrations or radiated at a dose of 8 Gy, 33 out of the 84 total 
miRNAs were modified. Interestingly, the most significant changes were observed when both treatments 




As the PCR array contains only one well for each of the miRNAs studied, it was neccesary to corroborate 
these results with speficic qPCRs. Due to their relevance in breast cancer pathogenesis, we selected a 
specific set of eight miRNAs to validate this data: miR-20b, miR-93, miR-17, miR-20a, miR-19a, miR-
29a, miR-15a, miR-19a and miR-141. Most of these miRNAs belong to highly conserved miRNAs 
clusters whose expression is increased in a wide spectrum of cancers, including breast cancer. The miR-
17-92 cluster encodes for six mature miRNAs, comprising miR-17, miR-20a and miR-19a as the most 
oncogenic ones. Besides, there are two paralogue gene clusters, miR-106a-363 and miR-106b-25, which 
encodes for miR-20b, miR-93 and miR-19a (Fang et al., 2017). These miRNA clusters have demonstrated 
a cooperative function in regulating targeted gene expression.  
The miR-17-92 cluster was found to be overexpressed in breast tumours. Although there are controversial 
findings on its role in breast cancer pathogenesis, this cluster is considered to have a oncogenic behaviour 
(Fang et al., 2017). For example, miR-20a and miR-19a, members of this cluster, are mainly involved in 
PTEN regulation, which is a key tumour suppressor gene. Concretely, PTEN encodes for a phosphatase 
which downregulates PI3K/AKT signalling pathway, related with cell motility, invasion, proliferation 
and survival (Carbognin et al. 2019; Hamam et al. 2017). In our work, both melatonin and radiation 
treatments significantly reduced miR-20a and miR-19a relative expression. Besides, when melatonin was 
added to the culture media before radiation, the inhibition was even higher.  
Regarding miR-17, radiation alone induced a significant upregulation which correlates with c-Myc 
overexpression and PTEN suppression (Nurzadeh et al., 2021). However, this undesirable radiation effect 
was counteracted by melatonin pre-treatment. Since there are many data in the previous literature that 
points to a correlation between miR-17-92 cluster overexpression and poor clinical state (Nurzadeh et al., 
2021), the ability of melatonin to diminish its expression may be considered as a positive beneficial effect 
in breast cancer.  
Other miRNAs (miR-93 and miR-29a) are related to angiogenic and metastatic processes. Hence, both 
miRNAs stimulate endothelial cell growth and metastasis in breast cancer (Fang et al., 2012) and their 
expression correlates with a migratory and invasive phenotype on MCF-7 cells (Singh & Mo, 2013). In 
our results, both miRNAs were underexpressed in melatonin pre-treated and radiated groups when 
compared to non-treated cells, and, once again both treatments were found to cooperate inducing the 
highest inhibition.  
miR-20b, a member of miR-106A-363 cluster, is also related with PI3K/AKT pathway. Specifically, 
overexpression of this miRNA induces Akt activation which in turn supresses PTEN and p53 proteins, 
thus promoting tumorigenic processes (Fang et al., 2017). Again, melatonin seems to exert a protective 
effect, since the inhibition of miR-20b was higher when this indolamine was added previously to the 
ionizing radiation treatment.  
miR-141 is a member of miR-200 family, a key regulator of EMT transition through E-cadherin 




act as an oncomiR when it is upregulated depending on the biological process (Nurzadeh et al., 2021; 
Kaban et al., 2019; Loh et al., 2019). Our study reveals an upregulation of this miRNA when cells were 
irradiated and a downregulation when melatonin was administered before radiation. As intriguing as it 
may be, there is controversial literature regarding its role in metastatic processes. As MCF-7 cells are a 
non-metastatic cell line, therefore, this miRNA could be underexpressed in this particular case. Moreover, 
it is important to add that some studies affirmed melatonin modulated miRNA expression, however this 
does necessarily mean these miRNAs are causative of tumoral processes (Ferreira et al., 2020).  
Finally, miR-15a is known for its tumour suppressor role and its overexpression is related with cyclin E1 
inhibition, which is primarily related with G1-S transition (Loh et al., 2019). Therefore, overexpression 
of miR-15a has beneficial effects for breast cancer progression. In our results, melatonin reduced the 
overexpressed miR-15a levels induced by radiation. However, recent studies indicate that miR-15a is 
downregulated in breast cancer (Luo et al., 2013) suggesting that melatonin can act as a regulator of 
deleterious overexpression of this miRNA, which can affect cytotoxicity. miRNA regulations and 
implications are summarized in Table 1.   
Table 1.  MiRNA expression patterns under radiotherapy and melatonin treatment and related molecular pathways. 
 
miRNA Radiation Radiation and melatonin Related pathway Associated event 
miR-20a Downregulated Downregulated PI3K/AKT/mTOR Invasion, proliferation and survival 
miR-19a Downregulated Downregulated PI3K/AKT/mTOR Invasion, proliferation and survival 
miR-17 Upregulated Downregulated PI3K/AKT/mTOR Promotes invasion and metastasis 
miR-93 Downregulated Downregulated PI3K/AKT/mTOR Promotes invasion and metastasis 
miR-20b Downregulated Downregulated PI3K/AKT/mTOR Cell growth, proliferation and apoptosis 
miR-141 Upregulated Downregulated Wnt/β-catenin Regulates EMT and invasion 
miR-15a Upregulated Upregulated Cyclin E1, E2F7 Anti-proliferative, G1-S cell cycle arrest 
miR-29a Downregulated Downregulated Akt3, VEGF, c-MYC Regulates EMT and metastasis 
 
We next determined the ability of melatonin to act as a modulator of some key kinases and their 
phosphorylation levels. Therefore, we focused our attention on biologically relevant signalling pathways 
involved in breast cancer, specifically studying Akt (PI3K/AKT) and p70S6 kinase (mTOR). In a 
proteome profiler assay, we found that melatonin treatment before radiation induced an inhibition on Akt 
and p70S6 kinases phosphorylation compared to radiated cells, suggesting a melatonin protective effect, 
as these are both tumour promoting kinases (Kong et al., 2020).  
Phosphorylation of Akt correlates with poor prognosis since when is active sends pro-survival signals to 
the cell (Carbognin et al., 2019). Moreover, activated Akt leads to mTOR activation, that activates, in 
turn, p70S6 kinase, increasing protein synthesis and cell proliferation (Kurgan et al., 2017). Suppression 
of PTEN activates the AKT/mTOR/p70S6K signaling axis, leading to a proliferative phenotype. When 
we tested Akt and p70S6K protein levels by western-blot, we found a modest stimulation on total Akt 
and p70S6K protein levels in the radiated cells, but this deleterious effect was counteracted by melatonin 




versions when cells were irradiated. Nevertheless, melatonin administration before radiation treatment 
was able once again to diminish p-Akt and p-p70S6 levels, proving its radio-sensitizing effects.  
In summary, the combination of melatonin with radiation in breast cancer cells has positive results in 
breast cancer treatment by inhibiting cell proliferation, decreasing AKT/mTOR/p70S6K signaling 
pathway and polarizing miRNAs expression levels towards a less proliferative and invasive phenotype. 
All these effects make us consider melatonin as a promising adjuvant agent to radiotherapy.  
Potential of melatonin as an adjuvant molecule for chemotherapy treatment 
Chemotherapy is traditionally one of the most common breast cancer treatments, despite its devastating 
side effects (Barzaman et al., 2020). The two chemotherapeutic agents used in this work are docetaxel 
and doxorubicin. The first one is a taxane that acts stabilizing microtubules through tubulin binding, 
consequently preventing cell division. The second one is an anthracycline that works by intercalation 
between double DNA helix, inhibiting DNA dependent DNA and RNA polymerases, interrupting DNA 
replication as a result (Saloustros et al., 2008; Czeczuga-Semeniuk et al., 2004). 
To prove potential action of melatonin as an adjuvant molecule for chemotherapeutic treatments, one of 
the first goals of this part of the work was to perform cell proliferation studies on MCF-7 cells. Firstly, 
we corroborate the anti-proliferative effect of the taxane and the anthracycline, founding a dose-
dependent inhibition. Even sub-pharmacological doses of these drugs showed a significant inhibition in 
comparison to control cells. Moreover, administration of physiological doses of melatonin potentiated 
the inhibition of cell proliferation triggered by docetaxel or doxorubicin. This synergistic effect may be 
due to addition of melatonin’s effect on G1-S transition delay, reducing the number of cells present in the 
S phase (Maroufi et al., 2020; Alonso-González et al. 2017). These results point to melatonin as an 
enhancer of chemotherapeutic agents’ effects, even when they are used at sub-pharmacological doses. 
Once established that melatonin enhanced the anti-proliferative effects of these chemotherapy agents, we 
next decided to evaluate whether this indolamine was able to modify chemotherapy-induced changes on 
miRNAs expression patterns. As mentioned before, for this purpose we employed a miRNA Human 
Breast Cancer microarray (MIHS-109ZA, Qiagen, USA). 
Regarding miRNA expression under chemotherapeutic treatment, our results demonstrated a change in 
miRNA expression levels in MCF-7 cells treated with chemotherapy and melatonin, either alone or in 
combination. The analysis revealed a general reduction of miRNA set in docetaxel-treated cells when 
compared to their respective non-treated control. However, when melatonin was added prior to the taxane, 
miRNA expression, despite remaining lower than non-treated cells, displayed higher levels than in 
docetaxel treatment. On the contrary, doxorubicin treated cells, exhibited higher levels than doxorubicin 
and melatonin pre-treated cells. Due to this high variability in miRNA microarrays, validation by specific 




Specific qPCRs disputed previous results regarding docetaxel and melatonin pre-treatment. In our results 
miR-20a, miR-17 and miR-19a which are members of miR-17/92 cluster, are generally downregulated 
after docetaxel treatment, except for miR-19a, whose expression levels are increased in respect to non-
treated cells. This may be due to multidrug resistance (MDR), as an upregulation of this miRNA has been 
observed in chemoresistant cancers (Wu et al., 2014). 
Despite of the effects observed in the microarray, melatonin addition to the culture media before docetaxel 
induced a general inhibition on the expression altered by the taxane. Since this cluster is mainly involved 
in PI3K/AKT signalling pathway, it is positive that these miRNAs are downregulated in MCF-7 breast 
cancer cells treated with melatonin, pointing to a protective effect in a way that fits with its anti-tumoral 
actions (Carbognin et al., 2019). This further proves the positive effect of melatonin in sensitizing breast 
cancer cells towards conventional treatments.  
In relation to miR-20b, a member of miR-106A-363 cluster, both docetaxel and melatonin treatments 
showed a downregulation. Consistently with the previous results, implication of this miRNA in Akt 
activation and PTEN and p53 regulation, demonstrates the positive effect of melatonin in the polarization 
towards apoptotic processes (Fang et al., 2017).  
Regarding miR-141, key regulator of EMT transition, we found overexpressed levels when cells were 
treated with docetaxel but a downregulation when melatonin was previously added to the culture media. 
This miRNA family overexpression has also been linked to chemotherapy resistance (Loh et al., 2019). 
In agreement with recent published works, our results were consistent as miR-141 expression is correlated 
with docetaxel resistance since inhibition of miR-141 enhanced response to docetaxel, inhibiting cell 
viability and increasing apoptosis in lung cancer (Wang et al., 2017). For that reason, melatonin’s ability 
to diminish docetaxel-induced miR-141 expression levels indicate a positive role of this indolamine to 
avoid chemotherapy resistance (Ferreira et al., 2020).  
Although the beneficial effects of miR-15a upregulation had been stated before, regarding 
chemotherapeutic treatment, its upregulation may have a different outcome. Literature has acknowledged 
the dual role of this miRNA as an oncogene and tumour suppressor depending on tissue 
microenvironmental characteristics (Krishnan, 2016). What can be said is that melatonin regulates this 
miRNA expression, that can be polarized by chemotherapeutic drugs used to treat breast cancer. This 
information is gathered in Table 2. 
It is important to consider that despite new findings may arise from the promising results regarding breast 
cancer molecular machinery and specifically to miRNA regulation, it is possible that melatonin is exerting 
its effects via subtle modulations of miRNA clusters and families and not a specific miRNA (Ferreira et 
al., 2020; Loh et al., 2019). Therefore, these results must be considered carefully as they might be part 




Table 2. Expression patterns of miRNAs under docetaxel and melatonin treatment and related molecular pathways. 
miRNA Docetaxel Docetaxel and melatonin Related pathway Associated event 
miR-20a Downregulated Downregulated PI3K/AKT/mTOR Invasion, proliferation and survival 
miR-19a Upregulated Downregulated PI3K/AKT/mTOR Invasion, proliferation and docetaxel 
resistance 
miR-17 Downregulated Downregulated PI3K/AKT/mTOR Promotes invasion and metastasis 
miR-93 No effect No effect PI3K/AKT/mTOR Promotes invasion and metastasis 
miR-20b Downregulated Downregulated PI3K/AKT/mTOR Cell growth, proliferation and apoptosis 
miR-141 Upregulated Downregulated Wnt/β-catenin Regulates EMT, invasion and 
chemoresistance 
miR-15a Upregulated Upregulated Cyclin E1, E2F7 Anti-proliferative, G1-S cell cycle arrest 
miR-29a No effect No effect Akt3, VEGF, c-MYC Regulates EMT, metastasis and docetaxel 
resistance 
 
In summary, present evidences place melatonin as a potential adjuvant for breast cancer conventional 
treatments. It is not a surprise after manifesting its oncostatic properties on estrogen-dependent breast 
cancer cell lines, restoring different molecular pathways that seem to be altered by cancer. In spite of this, 
not much attention has been paid to the intriguing molecular mechanisms underlying melatonin regulatory 
effects. Moreover, miRNAs implication in these regulatory actions is critical, as they represent specific 
and biologically relevant targets for this disease (Figure 1). This, added to the fact that miRNAs are 
promising molecules in personalized medical treatments, opens up a myriad of possibilities to tackle two 
major problems that remain unsolved in breast cancer: resistance and side effects.  
 
Figure 4. Breast cancer pathological processes and implication of selected miRNAs. Diagram of 
PI3K/AKT pathway signalling cascade is shown above.  
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CONCLUDING REMARKS AND FUTURE PERSPECTIVES 
In conclusion, physiological doses of melatonin enhance the antiproliferative effects of ionizing radiation 
and chemotherapeutic agents (docetaxel and doxorubicin) on MCF-7 breast cancer cells.  
Ionizing radiation and chemotherapy induce changes in breast cancer-related miRNA expression in MCF-
7 cells and melatonin added prior to these treatments modulates these changes towards a non-cancerous 
behaviour. 
Phosphorylation levels of two of the main proteins participating in PI3K/AKT/mTOR signalling axis 
(Akt and p70S6K) are reduced after irradiation of MCF-7 cells, being this effect potentiated by melatonin 
pre-treatment before ionizing radiation. 
To summarize, conventional breast cancer treatments have beneficial effects on MCF-7 regarding cancer 
progression. These effects are enhanced by melatonin, pointing at a synergistic effect when treatments 
are combined with this indolamine, sensitizing breast cancer cells towards conventional treatments.    
According to these findings, future research will be focused on validating doxorubicin preliminary results 
on miRNA expression patterns by specific qPCR. Other objective will be to establish the functional 
implication of selected miRNAs on gene expression changes and cell biology processes, transfecting 
MCF-7 cells to overexpress or to silence the selected miRNAs and studying their modulation on cell 
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